nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—CHRM3—ureter—kidney cancer	0.0166	0.336	CbGeAlD
Loxapine—HTR2A—urine—kidney cancer	0.0032	0.0647	CbGeAlD
Loxapine—HRH2—cardiac atrium—kidney cancer	0.00221	0.0447	CbGeAlD
Loxapine—ADRA1B—renal system—kidney cancer	0.00216	0.0436	CbGeAlD
Loxapine—ADRA1B—kidney—kidney cancer	0.00208	0.0422	CbGeAlD
Loxapine—HTR1D—kidney—kidney cancer	0.00152	0.0308	CbGeAlD
Loxapine—ADRB1—cardiac atrium—kidney cancer	0.00137	0.0277	CbGeAlD
Loxapine—CHRM3—renal system—kidney cancer	0.00132	0.0267	CbGeAlD
Loxapine—HTR1A—renal system—kidney cancer	0.00131	0.0266	CbGeAlD
Loxapine—CHRM3—kidney—kidney cancer	0.00128	0.0258	CbGeAlD
Loxapine—ADRA2C—nephron tubule—kidney cancer	0.00127	0.0257	CbGeAlD
Loxapine—HTR7—renal system—kidney cancer	0.00126	0.0254	CbGeAlD
Loxapine—HTR7—kidney—kidney cancer	0.00121	0.0246	CbGeAlD
Loxapine—ADRA1A—renal system—kidney cancer	0.00121	0.0245	CbGeAlD
Loxapine—SLC6A2—gonad—kidney cancer	0.00117	0.0236	CbGeAlD
Loxapine—Nausea—Temsirolimus—kidney cancer	0.00116	0.00173	CcSEcCtD
Loxapine—Dermatitis—Pazopanib—kidney cancer	0.00116	0.00173	CcSEcCtD
Loxapine—Bronchospasm—Capecitabine—kidney cancer	0.00116	0.00173	CcSEcCtD
Loxapine—Agitation—Vincristine—kidney cancer	0.00116	0.00172	CcSEcCtD
Loxapine—Headache—Pazopanib—kidney cancer	0.00116	0.00172	CcSEcCtD
Loxapine—ADRA2C—renal system—kidney cancer	0.00115	0.0233	CbGeAlD
Loxapine—Oedema—Dactinomycin—kidney cancer	0.00115	0.00171	CcSEcCtD
Loxapine—Hypoaesthesia—Paclitaxel—kidney cancer	0.00115	0.0017	CcSEcCtD
Loxapine—Leukopenia—Vincristine—kidney cancer	0.00113	0.00168	CcSEcCtD
Loxapine—Thrombocytopenia—Dactinomycin—kidney cancer	0.00113	0.00168	CcSEcCtD
Loxapine—Dyspnoea—Sorafenib—kidney cancer	0.00113	0.00168	CcSEcCtD
Loxapine—HTR7—gonad—kidney cancer	0.00113	0.0228	CbGeAlD
Loxapine—Dry eye—Doxorubicin—kidney cancer	0.00112	0.00167	CcSEcCtD
Loxapine—ADRA2C—kidney—kidney cancer	0.00112	0.0226	CbGeAlD
Loxapine—Insomnia—Sunitinib—kidney cancer	0.0011	0.00164	CcSEcCtD
Loxapine—Nausea—Pazopanib—kidney cancer	0.0011	0.00163	CcSEcCtD
Loxapine—Paraesthesia—Sunitinib—kidney cancer	0.00109	0.00163	CcSEcCtD
Loxapine—Convulsion—Vincristine—kidney cancer	0.00109	0.00163	CcSEcCtD
Loxapine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00109	0.00162	CcSEcCtD
Loxapine—Fatigue—Sorafenib—kidney cancer	0.00109	0.00162	CcSEcCtD
Loxapine—Hypertension—Vincristine—kidney cancer	0.00109	0.00162	CcSEcCtD
Loxapine—ADRA2C—cortex of kidney—kidney cancer	0.00109	0.022	CbGeAlD
Loxapine—Dyspnoea—Sunitinib—kidney cancer	0.00109	0.00161	CcSEcCtD
Loxapine—Constipation—Sorafenib—kidney cancer	0.00108	0.00161	CcSEcCtD
Loxapine—Hypersensitivity—Vinblastine—kidney cancer	0.00108	0.0016	CcSEcCtD
Loxapine—Photosensitivity reaction—Capecitabine—kidney cancer	0.00108	0.0016	CcSEcCtD
Loxapine—Weight increased—Capecitabine—kidney cancer	0.00107	0.0016	CcSEcCtD
Loxapine—Hypersensitivity—Everolimus—kidney cancer	0.00107	0.0016	CcSEcCtD
Loxapine—Leukopenia—Gemcitabine—kidney cancer	0.00107	0.00159	CcSEcCtD
Loxapine—Weight decreased—Capecitabine—kidney cancer	0.00107	0.00159	CcSEcCtD
Loxapine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00105	0.00156	CcSEcCtD
Loxapine—Asthenia—Vinblastine—kidney cancer	0.00105	0.00156	CcSEcCtD
Loxapine—Fatigue—Sunitinib—kidney cancer	0.00105	0.00156	CcSEcCtD
Loxapine—Asthenia—Everolimus—kidney cancer	0.00105	0.00156	CcSEcCtD
Loxapine—Cough—Gemcitabine—kidney cancer	0.00104	0.00155	CcSEcCtD
Loxapine—Angiopathy—Paclitaxel—kidney cancer	0.00104	0.00155	CcSEcCtD
Loxapine—Constipation—Sunitinib—kidney cancer	0.00104	0.00155	CcSEcCtD
Loxapine—Mediastinal disorder—Paclitaxel—kidney cancer	0.00104	0.00154	CcSEcCtD
Loxapine—Renal failure—Capecitabine—kidney cancer	0.00103	0.00154	CcSEcCtD
Loxapine—ADRA2C—cardiac atrium—kidney cancer	0.00103	0.0209	CbGeAlD
Loxapine—Hypertension—Gemcitabine—kidney cancer	0.00103	0.00154	CcSEcCtD
Loxapine—Pruritus—Everolimus—kidney cancer	0.00103	0.00153	CcSEcCtD
Loxapine—Oedema—Vincristine—kidney cancer	0.00103	0.00153	CcSEcCtD
Loxapine—Jaundice—Capecitabine—kidney cancer	0.00103	0.00153	CcSEcCtD
Loxapine—Chest pain—Gemcitabine—kidney cancer	0.00102	0.00152	CcSEcCtD
Loxapine—Alopecia—Paclitaxel—kidney cancer	0.00102	0.00151	CcSEcCtD
Loxapine—Nervous system disorder—Vincristine—kidney cancer	0.00101	0.0015	CcSEcCtD
Loxapine—Asthenia—Erlotinib—kidney cancer	0.00101	0.0015	CcSEcCtD
Loxapine—Thrombocytopenia—Vincristine—kidney cancer	0.00101	0.0015	CcSEcCtD
Loxapine—Photosensitivity—Doxorubicin—kidney cancer	0.001	0.00149	CcSEcCtD
Loxapine—Pruritus—Erlotinib—kidney cancer	0.000995	0.00148	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—kidney cancer	0.000993	0.00148	CcSEcCtD
Loxapine—Tension—Paclitaxel—kidney cancer	0.000983	0.00146	CcSEcCtD
Loxapine—Agranulocytosis—Capecitabine—kidney cancer	0.000982	0.00146	CcSEcCtD
Loxapine—Dysgeusia—Paclitaxel—kidney cancer	0.000981	0.00146	CcSEcCtD
Loxapine—Oedema—Gemcitabine—kidney cancer	0.000977	0.00145	CcSEcCtD
Loxapine—Dizziness—Vinblastine—kidney cancer	0.000967	0.00144	CcSEcCtD
Loxapine—Dizziness—Everolimus—kidney cancer	0.000964	0.00143	CcSEcCtD
Loxapine—Muscle spasms—Paclitaxel—kidney cancer	0.000963	0.00143	CcSEcCtD
Loxapine—Hypotension—Vincristine—kidney cancer	0.000962	0.00143	CcSEcCtD
Loxapine—Nervous system disorder—Gemcitabine—kidney cancer	0.000958	0.00142	CcSEcCtD
Loxapine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000956	0.00142	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—kidney cancer	0.000949	0.00141	CcSEcCtD
Loxapine—Hepatitis—Capecitabine—kidney cancer	0.000944	0.00141	CcSEcCtD
Loxapine—Vision blurred—Paclitaxel—kidney cancer	0.000944	0.0014	CcSEcCtD
Loxapine—Hypoaesthesia—Capecitabine—kidney cancer	0.00094	0.0014	CcSEcCtD
Loxapine—Tremor—Paclitaxel—kidney cancer	0.000939	0.0014	CcSEcCtD
Loxapine—Hypersensitivity—Sorafenib—kidney cancer	0.000932	0.00139	CcSEcCtD
Loxapine—Insomnia—Vincristine—kidney cancer	0.000931	0.00139	CcSEcCtD
Loxapine—Vomiting—Vinblastine—kidney cancer	0.00093	0.00138	CcSEcCtD
Loxapine—Dizziness—Erlotinib—kidney cancer	0.00093	0.00138	CcSEcCtD
Loxapine—Vomiting—Everolimus—kidney cancer	0.000926	0.00138	CcSEcCtD
Loxapine—Paraesthesia—Vincristine—kidney cancer	0.000924	0.00138	CcSEcCtD
Loxapine—Agitation—Paclitaxel—kidney cancer	0.000921	0.00137	CcSEcCtD
Loxapine—Rash—Everolimus—kidney cancer	0.000919	0.00137	CcSEcCtD
Loxapine—Dermatitis—Everolimus—kidney cancer	0.000918	0.00137	CcSEcCtD
Loxapine—Headache—Vinblastine—kidney cancer	0.000916	0.00136	CcSEcCtD
Loxapine—Headache—Everolimus—kidney cancer	0.000913	0.00136	CcSEcCtD
Loxapine—Hypotension—Gemcitabine—kidney cancer	0.000913	0.00136	CcSEcCtD
Loxapine—Asthenia—Sorafenib—kidney cancer	0.000907	0.00135	CcSEcCtD
Loxapine—Syncope—Paclitaxel—kidney cancer	0.000898	0.00134	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000898	0.00134	CcSEcCtD
Loxapine—Leukopenia—Paclitaxel—kidney cancer	0.000897	0.00133	CcSEcCtD
Loxapine—Hypersensitivity—Sunitinib—kidney cancer	0.000897	0.00133	CcSEcCtD
Loxapine—Pruritus—Sorafenib—kidney cancer	0.000895	0.00133	CcSEcCtD
Loxapine—Vomiting—Erlotinib—kidney cancer	0.000894	0.00133	CcSEcCtD
Loxapine—Azelastine—CYP1A1—kidney cancer	0.000893	0.207	CrCbGaD
Loxapine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000889	0.00132	CcSEcCtD
Loxapine—Fatigue—Vincristine—kidney cancer	0.000887	0.00132	CcSEcCtD
Loxapine—Rash—Erlotinib—kidney cancer	0.000886	0.00132	CcSEcCtD
Loxapine—Dermatitis—Erlotinib—kidney cancer	0.000886	0.00132	CcSEcCtD
Loxapine—Insomnia—Gemcitabine—kidney cancer	0.000883	0.00131	CcSEcCtD
Loxapine—Headache—Erlotinib—kidney cancer	0.000881	0.00131	CcSEcCtD
Loxapine—Loss of consciousness—Paclitaxel—kidney cancer	0.00088	0.00131	CcSEcCtD
Loxapine—Constipation—Vincristine—kidney cancer	0.00088	0.00131	CcSEcCtD
Loxapine—Paraesthesia—Gemcitabine—kidney cancer	0.000877	0.0013	CcSEcCtD
Loxapine—Cough—Paclitaxel—kidney cancer	0.000874	0.0013	CcSEcCtD
Loxapine—Asthenia—Sunitinib—kidney cancer	0.000873	0.0013	CcSEcCtD
Loxapine—Dyspnoea—Gemcitabine—kidney cancer	0.000871	0.0013	CcSEcCtD
Loxapine—Nausea—Vinblastine—kidney cancer	0.000869	0.00129	CcSEcCtD
Loxapine—Somnolence—Gemcitabine—kidney cancer	0.000868	0.00129	CcSEcCtD
Loxapine—Convulsion—Paclitaxel—kidney cancer	0.000868	0.00129	CcSEcCtD
Loxapine—ADRA2A—cortex of kidney—kidney cancer	0.000867	0.0175	CbGeAlD
Loxapine—Nausea—Everolimus—kidney cancer	0.000865	0.00129	CcSEcCtD
Loxapine—Hypertension—Paclitaxel—kidney cancer	0.000865	0.00129	CcSEcCtD
Loxapine—Pruritus—Sunitinib—kidney cancer	0.000861	0.00128	CcSEcCtD
Loxapine—Angiopathy—Capecitabine—kidney cancer	0.000857	0.00127	CcSEcCtD
Loxapine—Chest pain—Paclitaxel—kidney cancer	0.000853	0.00127	CcSEcCtD
Loxapine—Mediastinal disorder—Capecitabine—kidney cancer	0.000851	0.00127	CcSEcCtD
Loxapine—Hypersensitivity—Dactinomycin—kidney cancer	0.000849	0.00126	CcSEcCtD
Loxapine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000843	0.00125	CcSEcCtD
Loxapine—Fatigue—Gemcitabine—kidney cancer	0.000842	0.00125	CcSEcCtD
Loxapine—Dizziness—Sorafenib—kidney cancer	0.000836	0.00124	CcSEcCtD
Loxapine—Constipation—Gemcitabine—kidney cancer	0.000835	0.00124	CcSEcCtD
Loxapine—Nausea—Erlotinib—kidney cancer	0.000835	0.00124	CcSEcCtD
Loxapine—Alopecia—Capecitabine—kidney cancer	0.000835	0.00124	CcSEcCtD
Loxapine—Dry mouth—Paclitaxel—kidney cancer	0.000834	0.00124	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—kidney cancer	0.000827	0.00123	CcSEcCtD
Loxapine—ADRA2A—gonad—kidney cancer	0.000826	0.0167	CbGeAlD
Loxapine—ADRA2A—cardiac atrium—kidney cancer	0.000825	0.0167	CbGeAlD
Loxapine—Confusional state—Paclitaxel—kidney cancer	0.000824	0.00123	CcSEcCtD
Loxapine—Oedema—Paclitaxel—kidney cancer	0.000818	0.00122	CcSEcCtD
Loxapine—Dysgeusia—Capecitabine—kidney cancer	0.000805	0.0012	CcSEcCtD
Loxapine—Dizziness—Sunitinib—kidney cancer	0.000805	0.0012	CcSEcCtD
Loxapine—Feeling abnormal—Gemcitabine—kidney cancer	0.000805	0.0012	CcSEcCtD
Loxapine—Shock—Paclitaxel—kidney cancer	0.000804	0.0012	CcSEcCtD
Loxapine—Vomiting—Sorafenib—kidney cancer	0.000804	0.0012	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000804	0.0012	CcSEcCtD
Loxapine—Nervous system disorder—Paclitaxel—kidney cancer	0.000802	0.00119	CcSEcCtD
Loxapine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000801	0.00119	CcSEcCtD
Loxapine—Tachycardia—Paclitaxel—kidney cancer	0.000798	0.00119	CcSEcCtD
Loxapine—Rash—Sorafenib—kidney cancer	0.000797	0.00119	CcSEcCtD
Loxapine—Dermatitis—Sorafenib—kidney cancer	0.000797	0.00119	CcSEcCtD
Loxapine—Headache—Sorafenib—kidney cancer	0.000792	0.00118	CcSEcCtD
Loxapine—Muscle spasms—Capecitabine—kidney cancer	0.00079	0.00118	CcSEcCtD
Loxapine—HTR2A—renal system—kidney cancer	0.000783	0.0158	CbGeAlD
Loxapine—Vision blurred—Capecitabine—kidney cancer	0.000775	0.00115	CcSEcCtD
Loxapine—Vomiting—Sunitinib—kidney cancer	0.000774	0.00115	CcSEcCtD
Loxapine—Tremor—Capecitabine—kidney cancer	0.00077	0.00115	CcSEcCtD
Loxapine—Rash—Sunitinib—kidney cancer	0.000767	0.00114	CcSEcCtD
Loxapine—Dermatitis—Sunitinib—kidney cancer	0.000767	0.00114	CcSEcCtD
Loxapine—Hypotension—Paclitaxel—kidney cancer	0.000764	0.00114	CcSEcCtD
Loxapine—Headache—Sunitinib—kidney cancer	0.000762	0.00113	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—kidney cancer	0.000761	0.00113	CcSEcCtD
Loxapine—Hypersensitivity—Vincristine—kidney cancer	0.000758	0.00113	CcSEcCtD
Loxapine—HTR2A—kidney—kidney cancer	0.000757	0.0153	CbGeAlD
Loxapine—Nausea—Sorafenib—kidney cancer	0.000751	0.00112	CcSEcCtD
Loxapine—Insomnia—Paclitaxel—kidney cancer	0.000739	0.0011	CcSEcCtD
Loxapine—Asthenia—Vincristine—kidney cancer	0.000739	0.0011	CcSEcCtD
Loxapine—Syncope—Capecitabine—kidney cancer	0.000737	0.0011	CcSEcCtD
Loxapine—Leukopenia—Capecitabine—kidney cancer	0.000736	0.00109	CcSEcCtD
Loxapine—Paraesthesia—Paclitaxel—kidney cancer	0.000734	0.00109	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—kidney cancer	0.000733	0.00109	CcSEcCtD
Loxapine—Dyspnoea—Paclitaxel—kidney cancer	0.000729	0.00108	CcSEcCtD
Loxapine—Somnolence—Paclitaxel—kidney cancer	0.000727	0.00108	CcSEcCtD
Loxapine—Rash—Dactinomycin—kidney cancer	0.000726	0.00108	CcSEcCtD
Loxapine—Nausea—Sunitinib—kidney cancer	0.000723	0.00108	CcSEcCtD
Loxapine—Loss of consciousness—Capecitabine—kidney cancer	0.000723	0.00108	CcSEcCtD
Loxapine—Cough—Capecitabine—kidney cancer	0.000717	0.00107	CcSEcCtD
Loxapine—Hypertension—Capecitabine—kidney cancer	0.00071	0.00106	CcSEcCtD
Loxapine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000706	0.00105	CcSEcCtD
Loxapine—Fatigue—Paclitaxel—kidney cancer	0.000705	0.00105	CcSEcCtD
Loxapine—HTR2A—gonad—kidney cancer	0.000702	0.0142	CbGeAlD
Loxapine—Asthenia—Gemcitabine—kidney cancer	0.000701	0.00104	CcSEcCtD
Loxapine—Chest pain—Capecitabine—kidney cancer	0.0007	0.00104	CcSEcCtD
Loxapine—Constipation—Paclitaxel—kidney cancer	0.000699	0.00104	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000694	0.00103	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—kidney cancer	0.000692	0.00103	CcSEcCtD
Loxapine—Pruritus—Gemcitabine—kidney cancer	0.000691	0.00103	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—kidney cancer	0.000688	0.00102	CcSEcCtD
Loxapine—Dry mouth—Capecitabine—kidney cancer	0.000685	0.00102	CcSEcCtD
Loxapine—Nausea—Dactinomycin—kidney cancer	0.000684	0.00102	CcSEcCtD
Loxapine—Dizziness—Vincristine—kidney cancer	0.000681	0.00101	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—kidney cancer	0.000678	0.00101	CcSEcCtD
Loxapine—Confusional state—Capecitabine—kidney cancer	0.000677	0.00101	CcSEcCtD
Loxapine—Feeling abnormal—Paclitaxel—kidney cancer	0.000674	0.001	CcSEcCtD
Loxapine—Oedema—Capecitabine—kidney cancer	0.000671	0.000998	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—kidney cancer	0.000667	0.000992	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—kidney cancer	0.000661	0.000984	CcSEcCtD
Loxapine—Shock—Capecitabine—kidney cancer	0.00066	0.000982	CcSEcCtD
Loxapine—Nervous system disorder—Capecitabine—kidney cancer	0.000658	0.000979	CcSEcCtD
Loxapine—Thrombocytopenia—Capecitabine—kidney cancer	0.000657	0.000977	CcSEcCtD
Loxapine—Tachycardia—Capecitabine—kidney cancer	0.000655	0.000974	CcSEcCtD
Loxapine—Vomiting—Vincristine—kidney cancer	0.000655	0.000974	CcSEcCtD
Loxapine—Rash—Vincristine—kidney cancer	0.000649	0.000966	CcSEcCtD
Loxapine—Dermatitis—Vincristine—kidney cancer	0.000648	0.000965	CcSEcCtD
Loxapine—Headache—Vincristine—kidney cancer	0.000645	0.00096	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—kidney cancer	0.000633	0.000942	CcSEcCtD
Loxapine—Hypotension—Capecitabine—kidney cancer	0.000627	0.000933	CcSEcCtD
Loxapine—Vomiting—Gemcitabine—kidney cancer	0.000621	0.000924	CcSEcCtD
Loxapine—Rash—Gemcitabine—kidney cancer	0.000616	0.000916	CcSEcCtD
Loxapine—Dermatitis—Gemcitabine—kidney cancer	0.000615	0.000915	CcSEcCtD
Loxapine—Headache—Gemcitabine—kidney cancer	0.000612	0.00091	CcSEcCtD
Loxapine—Nausea—Vincristine—kidney cancer	0.000611	0.00091	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—kidney cancer	0.000609	0.000906	CcSEcCtD
Loxapine—Insomnia—Capecitabine—kidney cancer	0.000607	0.000903	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000606	0.000901	CcSEcCtD
Loxapine—Paraesthesia—Capecitabine—kidney cancer	0.000602	0.000896	CcSEcCtD
Loxapine—Hypersensitivity—Paclitaxel—kidney cancer	0.000602	0.000896	CcSEcCtD
Loxapine—Dyspnoea—Capecitabine—kidney cancer	0.000598	0.00089	CcSEcCtD
Loxapine—Asthenia—Paclitaxel—kidney cancer	0.000587	0.000873	CcSEcCtD
Loxapine—Nausea—Gemcitabine—kidney cancer	0.00058	0.000863	CcSEcCtD
Loxapine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000579	0.000862	CcSEcCtD
Loxapine—Fatigue—Capecitabine—kidney cancer	0.000578	0.000861	CcSEcCtD
Loxapine—Pruritus—Paclitaxel—kidney cancer	0.000578	0.000861	CcSEcCtD
Loxapine—Constipation—Capecitabine—kidney cancer	0.000574	0.000854	CcSEcCtD
Loxapine—Feeling abnormal—Capecitabine—kidney cancer	0.000553	0.000823	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—kidney cancer	0.000552	0.000822	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000549	0.000816	CcSEcCtD
Loxapine—Dizziness—Paclitaxel—kidney cancer	0.000541	0.000804	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—kidney cancer	0.000538	0.0008	CcSEcCtD
Loxapine—Tension—Doxorubicin—kidney cancer	0.00052	0.000774	CcSEcCtD
Loxapine—Vomiting—Paclitaxel—kidney cancer	0.00052	0.000773	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—kidney cancer	0.000519	0.000772	CcSEcCtD
Loxapine—Rash—Paclitaxel—kidney cancer	0.000516	0.000767	CcSEcCtD
Loxapine—Dermatitis—Paclitaxel—kidney cancer	0.000515	0.000766	CcSEcCtD
Loxapine—Headache—Paclitaxel—kidney cancer	0.000512	0.000762	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—kidney cancer	0.000509	0.000758	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—kidney cancer	0.000499	0.000743	CcSEcCtD
Loxapine—Hypersensitivity—Capecitabine—kidney cancer	0.000494	0.000736	CcSEcCtD
Loxapine—Agitation—Doxorubicin—kidney cancer	0.000487	0.000725	CcSEcCtD
Loxapine—Nausea—Paclitaxel—kidney cancer	0.000486	0.000723	CcSEcCtD
Loxapine—Asthenia—Capecitabine—kidney cancer	0.000481	0.000716	CcSEcCtD
Loxapine—Syncope—Doxorubicin—kidney cancer	0.000475	0.000707	CcSEcCtD
Loxapine—Pruritus—Capecitabine—kidney cancer	0.000475	0.000706	CcSEcCtD
Loxapine—Azelastine—ABCB1—kidney cancer	0.000475	0.11	CrCbGaD
Loxapine—Leukopenia—Doxorubicin—kidney cancer	0.000474	0.000706	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—kidney cancer	0.000466	0.000693	CcSEcCtD
Loxapine—Cough—Doxorubicin—kidney cancer	0.000462	0.000688	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—kidney cancer	0.000459	0.000683	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—kidney cancer	0.000458	0.000681	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—kidney cancer	0.000451	0.000671	CcSEcCtD
Loxapine—Dizziness—Capecitabine—kidney cancer	0.000444	0.00066	CcSEcCtD
Loxapine—Diazepam—PTGS1—kidney cancer	0.000443	0.103	CrCbGaD
Loxapine—Dry mouth—Doxorubicin—kidney cancer	0.000441	0.000657	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—kidney cancer	0.000436	0.000649	CcSEcCtD
Loxapine—Oedema—Doxorubicin—kidney cancer	0.000433	0.000644	CcSEcCtD
Loxapine—Vomiting—Capecitabine—kidney cancer	0.000427	0.000635	CcSEcCtD
Loxapine—Shock—Doxorubicin—kidney cancer	0.000426	0.000633	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—kidney cancer	0.000424	0.000631	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—kidney cancer	0.000423	0.00063	CcSEcCtD
Loxapine—Rash—Capecitabine—kidney cancer	0.000423	0.000629	CcSEcCtD
Loxapine—Dermatitis—Capecitabine—kidney cancer	0.000423	0.000629	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—kidney cancer	0.000422	0.000628	CcSEcCtD
Loxapine—Headache—Capecitabine—kidney cancer	0.00042	0.000625	CcSEcCtD
Loxapine—Olanzapine—ABCB1—kidney cancer	0.000408	0.0946	CrCbGaD
Loxapine—Hypotension—Doxorubicin—kidney cancer	0.000404	0.000601	CcSEcCtD
Loxapine—Clozapine—CYP1A1—kidney cancer	0.0004	0.0929	CrCbGaD
Loxapine—Nausea—Capecitabine—kidney cancer	0.000399	0.000593	CcSEcCtD
Loxapine—Trazodone—ABCB1—kidney cancer	0.000394	0.0914	CrCbGaD
Loxapine—Insomnia—Doxorubicin—kidney cancer	0.000391	0.000582	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—kidney cancer	0.000388	0.000578	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—kidney cancer	0.000386	0.000574	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—kidney cancer	0.000384	0.000572	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000373	0.000556	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—kidney cancer	0.000373	0.000555	CcSEcCtD
Loxapine—Constipation—Doxorubicin—kidney cancer	0.00037	0.00055	CcSEcCtD
Loxapine—Clobazam—ABCB1—kidney cancer	0.000369	0.0856	CrCbGaD
Loxapine—Feeling abnormal—Doxorubicin—kidney cancer	0.000356	0.00053	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—kidney cancer	0.000319	0.000474	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—kidney cancer	0.00031	0.000462	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—kidney cancer	0.000306	0.000455	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—kidney cancer	0.000286	0.000426	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—kidney cancer	0.000275	0.000409	CcSEcCtD
Loxapine—Rash—Doxorubicin—kidney cancer	0.000273	0.000406	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—kidney cancer	0.000272	0.000405	CcSEcCtD
Loxapine—Headache—Doxorubicin—kidney cancer	0.000271	0.000403	CcSEcCtD
Loxapine—Nausea—Doxorubicin—kidney cancer	0.000257	0.000382	CcSEcCtD
Loxapine—Trifluoperazine—ABCB1—kidney cancer	0.000255	0.0592	CrCbGaD
Loxapine—Quetiapine—ABCB1—kidney cancer	0.000247	0.0574	CrCbGaD
Loxapine—Diazepam—ABCB1—kidney cancer	0.000215	0.05	CrCbGaD
Loxapine—Clozapine—ABCB1—kidney cancer	0.000213	0.0494	CrCbGaD
Loxapine—CHRM5—Signaling Pathways—MAPK3—kidney cancer	1.45e-05	5.28e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—RAF1—kidney cancer	1.45e-05	5.27e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—KRAS—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—KRAS—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—RELA—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCND1—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MAPK1—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PTEN—kidney cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	1.44e-05	5.24e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—JUN—kidney cancer	1.44e-05	5.24e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.44e-05	5.24e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	1.43e-05	5.23e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCND1—kidney cancer	1.43e-05	5.22e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ERBB2—kidney cancer	1.43e-05	5.22e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	1.43e-05	5.21e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—KRAS—kidney cancer	1.43e-05	5.21e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—JUN—kidney cancer	1.43e-05	5.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—kidney cancer	1.43e-05	5.21e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	1.43e-05	5.2e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	1.42e-05	5.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTEN—kidney cancer	1.42e-05	5.19e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—RAF1—kidney cancer	1.42e-05	5.19e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	1.42e-05	5.18e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—RAF1—kidney cancer	1.42e-05	5.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	1.42e-05	5.18e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	1.42e-05	5.17e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—RELA—kidney cancer	1.42e-05	5.16e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RAF1—kidney cancer	1.41e-05	5.16e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—RELA—kidney cancer	1.41e-05	5.15e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MTOR—kidney cancer	1.41e-05	5.15e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RAF1—kidney cancer	1.41e-05	5.14e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—kidney cancer	1.41e-05	5.14e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RELA—kidney cancer	1.41e-05	5.14e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ERBB2—kidney cancer	1.41e-05	5.13e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	1.41e-05	5.13e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—kidney cancer	1.41e-05	5.13e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—kidney cancer	1.4e-05	5.12e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RELA—kidney cancer	1.4e-05	5.12e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	1.4e-05	5.12e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KRAS—kidney cancer	1.4e-05	5.11e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	1.4e-05	5.1e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RAF1—kidney cancer	1.4e-05	5.09e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—kidney cancer	1.39e-05	5.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	1.39e-05	5.08e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCND1—kidney cancer	1.39e-05	5.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RELA—kidney cancer	1.39e-05	5.07e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—JUN—kidney cancer	1.39e-05	5.07e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PTEN—kidney cancer	1.39e-05	5.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MTOR—kidney cancer	1.39e-05	5.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RELA—kidney cancer	1.39e-05	5.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MTOR—kidney cancer	1.39e-05	5.05e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PTEN—kidney cancer	1.38e-05	5.04e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	1.38e-05	5.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MTOR—kidney cancer	1.38e-05	5.04e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK3—kidney cancer	1.38e-05	5.03e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	1.38e-05	5.03e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MAPK1—kidney cancer	1.38e-05	5.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	1.38e-05	5.02e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KRAS—kidney cancer	1.38e-05	5.02e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MTOR—kidney cancer	1.38e-05	5.02e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	1.37e-05	5e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—JUN—kidney cancer	1.37e-05	4.99e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MTOR—kidney cancer	1.36e-05	4.97e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK3—kidney cancer	1.36e-05	4.97e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	1.36e-05	4.96e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KRAS—kidney cancer	1.36e-05	4.96e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	1.36e-05	4.95e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTEN—kidney cancer	1.34e-05	4.9e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—kidney cancer	1.34e-05	4.9e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—kidney cancer	1.32e-05	4.83e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CDKN1B—kidney cancer	1.32e-05	4.83e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—PIK3CA—kidney cancer	1.32e-05	4.83e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	1.32e-05	4.82e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—PIK3CA—kidney cancer	1.32e-05	4.82e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	1.31e-05	4.79e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK1—kidney cancer	1.31e-05	4.79e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—kidney cancer	1.31e-05	4.78e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTEN—kidney cancer	1.31e-05	4.76e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	1.3e-05	4.75e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	1.3e-05	4.75e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KRAS—kidney cancer	1.3e-05	4.75e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	1.3e-05	4.74e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	1.3e-05	4.74e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	1.3e-05	4.73e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—kidney cancer	1.3e-05	4.73e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK1—kidney cancer	1.3e-05	4.73e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	1.29e-05	4.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	1.29e-05	4.71e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RELA—kidney cancer	1.29e-05	4.7e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	1.29e-05	4.69e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—kidney cancer	1.28e-05	4.67e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	1.28e-05	4.67e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	1.28e-05	4.67e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—kidney cancer	1.28e-05	4.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	1.28e-05	4.65e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—kidney cancer	1.28e-05	4.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—kidney cancer	1.27e-05	4.64e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—kidney cancer	1.27e-05	4.63e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—kidney cancer	1.27e-05	4.63e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—PIK3CA—kidney cancer	1.27e-05	4.62e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—kidney cancer	1.26e-05	4.61e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCND1—kidney cancer	1.26e-05	4.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	1.26e-05	4.61e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—JUN—kidney cancer	1.26e-05	4.6e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—kidney cancer	1.25e-05	4.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—kidney cancer	1.25e-05	4.57e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—kidney cancer	1.25e-05	4.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—kidney cancer	1.25e-05	4.55e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	1.25e-05	4.55e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—kidney cancer	1.25e-05	4.55e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—kidney cancer	1.24e-05	4.54e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—kidney cancer	1.24e-05	4.53e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK3—kidney cancer	1.24e-05	4.53e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—JUN—kidney cancer	1.24e-05	4.52e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—kidney cancer	1.24e-05	4.52e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—kidney cancer	1.24e-05	4.52e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—JUN—kidney cancer	1.24e-05	4.51e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—kidney cancer	1.24e-05	4.51e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—JUN—kidney cancer	1.23e-05	4.5e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—kidney cancer	1.23e-05	4.5e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	1.23e-05	4.49e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—JUN—kidney cancer	1.23e-05	4.49e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	1.23e-05	4.48e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	1.23e-05	4.48e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	1.22e-05	4.47e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—kidney cancer	1.22e-05	4.47e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—kidney cancer	1.22e-05	4.46e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—kidney cancer	1.22e-05	4.45e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	1.22e-05	4.45e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—kidney cancer	1.22e-05	4.45e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—JUN—kidney cancer	1.22e-05	4.44e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	1.22e-05	4.44e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—JUN—kidney cancer	1.21e-05	4.43e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	1.21e-05	4.43e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	1.21e-05	4.41e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—kidney cancer	1.21e-05	4.41e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—kidney cancer	1.21e-05	4.4e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	1.21e-05	4.4e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—kidney cancer	1.2e-05	4.38e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—kidney cancer	1.2e-05	4.37e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	1.2e-05	4.36e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—kidney cancer	1.2e-05	4.36e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	1.19e-05	4.36e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—kidney cancer	1.19e-05	4.35e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—kidney cancer	1.19e-05	4.34e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—kidney cancer	1.19e-05	4.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	1.19e-05	4.32e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—kidney cancer	1.18e-05	4.31e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK1—kidney cancer	1.18e-05	4.31e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—kidney cancer	1.18e-05	4.3e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	1.17e-05	4.29e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	1.17e-05	4.27e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—kidney cancer	1.16e-05	4.23e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—kidney cancer	1.16e-05	4.22e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—kidney cancer	1.15e-05	4.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	1.15e-05	4.19e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—kidney cancer	1.15e-05	4.19e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—kidney cancer	1.14e-05	4.16e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—kidney cancer	1.13e-05	4.14e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	1.13e-05	4.12e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	1.13e-05	4.12e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK1—kidney cancer	1.13e-05	4.12e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—JUN—kidney cancer	1.13e-05	4.12e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—kidney cancer	1.12e-05	4.1e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK1—kidney cancer	1.12e-05	4.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	1.12e-05	4.08e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—kidney cancer	1.12e-05	4.07e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—kidney cancer	1.11e-05	4.07e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—kidney cancer	1.1e-05	4.03e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—kidney cancer	1.1e-05	4.02e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—kidney cancer	1.1e-05	4.02e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—kidney cancer	1.1e-05	4.01e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	1.09e-05	3.99e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	1.09e-05	3.98e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—kidney cancer	1.09e-05	3.97e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—kidney cancer	1.08e-05	3.95e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—kidney cancer	1.08e-05	3.94e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	1.08e-05	3.93e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	1.08e-05	3.92e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—kidney cancer	1.07e-05	3.92e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—kidney cancer	1.07e-05	3.89e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	1.06e-05	3.88e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	1.06e-05	3.87e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—kidney cancer	1.06e-05	3.87e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—kidney cancer	1.04e-05	3.8e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—kidney cancer	1.03e-05	3.76e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—kidney cancer	1.03e-05	3.74e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	1.02e-05	3.74e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—kidney cancer	1.02e-05	3.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	1.02e-05	3.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—kidney cancer	1.02e-05	3.71e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	1.02e-05	3.7e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	1.01e-05	3.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—kidney cancer	1.01e-05	3.7e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	1.01e-05	3.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	1e-05	3.66e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—kidney cancer	1e-05	3.66e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—kidney cancer	9.97e-06	3.64e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—kidney cancer	9.95e-06	3.63e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—kidney cancer	9.92e-06	3.62e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK1—kidney cancer	9.91e-06	3.62e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—kidney cancer	9.91e-06	3.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—kidney cancer	9.89e-06	3.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	9.86e-06	3.6e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—kidney cancer	9.82e-06	3.58e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	9.8e-06	3.57e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—kidney cancer	9.79e-06	3.57e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—kidney cancer	9.76e-06	3.56e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK1—kidney cancer	9.75e-06	3.56e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	9.75e-06	3.56e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK1—kidney cancer	9.73e-06	3.55e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	9.7e-06	3.54e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK1—kidney cancer	9.67e-06	3.53e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	9.58e-06	3.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	9.55e-06	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	9.48e-06	3.46e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—kidney cancer	9.48e-06	3.46e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—kidney cancer	9.43e-06	3.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—kidney cancer	9.36e-06	3.42e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	9.33e-06	3.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	9.33e-06	3.4e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—kidney cancer	9.21e-06	3.36e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—kidney cancer	9.21e-06	3.36e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—kidney cancer	9.19e-06	3.35e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—kidney cancer	9.17e-06	3.35e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—kidney cancer	9.16e-06	3.34e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—kidney cancer	9.13e-06	3.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—kidney cancer	9.07e-06	3.31e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—kidney cancer	9.05e-06	3.3e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—kidney cancer	9.03e-06	3.29e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	9.02e-06	3.29e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	8.87e-06	3.24e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—kidney cancer	8.6e-06	3.14e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	8.46e-06	3.09e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	8.45e-06	3.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	8.42e-06	3.07e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	8.39e-06	3.06e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	8.38e-06	3.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—kidney cancer	8.32e-06	3.04e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	8.31e-06	3.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	8.29e-06	3.02e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—kidney cancer	8.19e-06	2.99e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—kidney cancer	8.17e-06	2.98e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—kidney cancer	8.14e-06	2.97e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—kidney cancer	8.12e-06	2.96e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—kidney cancer	8.04e-06	2.93e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—kidney cancer	8.02e-06	2.92e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	7.7e-06	2.81e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—kidney cancer	7.45e-06	2.72e-05	CbGpPWpGaD
